Cardiometabolic risk factors in individuals with cystic fibrosis undergoing Elexacaftor/Tezacaftor/Ivacaftor therapy - Vienna 2024

Exploring new fields in adult cystic fibrosis

Chair(s): Andrea Gramegna, Cl?mence Martin

Session type: Oral presentation

Cardiometabolic risk factors in individuals with cystic fibrosis undergoing Elexacaftor/Tezacaftor/Ivacaftor therapy

Gloria Leonardi

EVENTS HOME

Previous presentation

Next presentation

Session content

Detection of antibiotic susceptibility in adult people with cystic fibrosis using a metagenomics approach

Sonja Van Scheijen

Replay

Poster

Abstract

Slides

Cystic fibrosis and the role of CFTR in circulating immune cells: a human single-cell atlas

Leander Jonckheere

Replay

Poster

Abstract

Slides

Effectiveness of ETI in people with Cystic Fibrosis and no F508del CFTR variant: a multicenter study in Greece

Aikaterini Manika

Replay

Poster

Abstract

Slides

A CFTR modulator therapy might improve ciliary beating in patients with cystic fibrosis

C?line Kempeneers

Replay

Poster

Abstract

Slides

Cardiometabolic risk factors in individuals with cystic fibrosis undergoing Elexacaftor/Tezacaftor/Ivacaftor therapy

Gloria Leonardi

Replay

Poster

Abstract

Slides

Limited effectiveness of elexacaftor-tezacaftor-ivacaftor on lung hyperinflation in adults with cystic fibrosis

Th Dh?te

Replay

Poster

Abstract

Slides

Regional ventilation evaluation of abnormalities of the lung in cystic fibrosis (ReVEAL-CF Study)

Grace Kavanagh

Replay

Poster

Abstract

Slides

Distal pulmonary arterial remodeling in end-stage cystic fibrosis

Astrid Vermaut

Replay

Abstract

Slides

VOC breath biomarkers for early detection and monitoring of acute pulmonary exacerbations in people with Cystic Fibrosis

Rodrigo Andres Floto

Replay

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}